Why Follow Osteoporosis Bone Builders with Antiresorptives?

After completing the planned course of a bone-building (anabolic) medicine, a follow-up medicine is usually recommended to preserve your gains; the exact drug and timing are individualized. Bone builders increase bone density and strength, but some of these gains may be lost over time once the medication is stopped ^[1]. Because bone-building medications have strict usage time limits, stopping them without a planned follow-up treatment means the benefits can gradually diminish. Antiresorptive medications act as a crucial next step to preserve and consolidate those hard-won bone density gains ^[2].

The Clinical Rationale for Sequential Therapy

This two-step approach is known as sequential therapy—using one type of medication followed by another to maximize and maintain bone strength. Bone is living tissue that constantly undergoes a cycle of being broken down (resorption) and rebuilt (formation).

• Step 1: Build. Medications like teriparatide and abaloparatide are anabolics that work primarily by stimulating bone formation. Romosozumab has a dual effect—it increases bone formation while also decreasing bone breakdown. Together, these drugs actively add new bone mass ^[3]. However, medical guidelines restrict their use to a specific duration (commonly 12 months for romosozumab, 18 months for abaloparatide, and up to 24 months for teriparatide, though exact labels can vary by country).
• Step 2: Protect. Because the strong bone-building signal stops when you finish the medication, your body’s natural breakdown process will resume, and some of the newly built bone may be lost over time ^[1]. Antiresorptive medications—such as bisphosphonates (like alendronate) or denosumab—work by slowing down the bone breakdown process. Taking them promptly after your anabolic treatment helps consolidate and preserve your new bone density ^[2].

The Importance of Treatment Order

Research into sequential therapy shows that the order of these medications matters significantly, particularly for very-high-risk patients. Starting with a bone builder and following it with an antiresorptive often produces larger gains in bone mineral density (BMD—a scan-based measure of how much mineral is packed into your bones) than reversing the order ^[4][5][6].

For example, studies show that when patients switch from teriparatide to denosumab, their bone mineral density actually continues to increase rather than just holding steady ^[7]. Needing a second medication does not mean your first treatment failed—it is the planned next phase of your care.

Choosing Your Follow-Up Medication

Your doctor will choose an antiresorptive based on your specific health profile. The choice between a bisphosphonate (which can be pills or an IV infusion) and denosumab (an injection) depends on factors such as your kidney function, blood calcium and vitamin D levels, upcoming dental procedures, and your ability to maintain follow-up appointments.

Important Safety Warning for Denosumab: If you and your doctor choose denosumab as your follow-up medication, it is critical that you receive your injections exactly on schedule (typically every 6 months). Delaying or stopping denosumab without a planned transition to another antiresorptive can cause a rapid rebound in bone turnover, leading to fast bone loss and an increased risk of multiple spinal fractures.

What Happens If You Stop Without a Follow-Up?

If your bone-building medication ends—whether it is a planned end-of-course or an unplanned interruption—and you do not start an antiresorptive, the benefits you gained will gradually wear off ^[1]. Your bone density will drop, and your risk of fractures could increase again.

To prevent a gap in your treatment, your clinician will help you schedule an exact transition date. Follow-up may include a medication review, calcium and kidney laboratory testing, and bone-density monitoring. Do not start, stop, skip, or switch your osteoporosis medication without contacting your prescribing clinician.